Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,801–3,825 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
· Cell Death Differ · 2013 · PMID 23538418 · validated civic_curation pubmed
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
· Cancer Discov · 2014 · PMID 24265153 · validated cbioportal_study pubmed
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
· Invest New Drugs · 2017 · PMID 28516360 · validated civic_curation pubmed
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
· Leukemia · 2013 · PMID 22858906 · validated civic_curation pubmed
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
· Blood · 2006 · PMID 16434489 · validated civic_curation pubmed
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
· Cancer Biol Ther · 2014 · PMID 24642870 · validated civic_curation pubmed

Showing 3,801–3,825 of 4,399 publications

← Previous
1
…
152
153
154
…
176
Next →

Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.

· Cancer Cell · 2014 · PMID 25453902 · validated civic_curation pubmed

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

· Proc Natl Acad Sci U S A · 2012 · PMID 23236167 · validated civic_curation pubmed

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.

· Oncotarget · 2017 · PMID 28077790 · validated civic_curation pubmed

A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.

· Cell Rep · 2018 · PMID 29949764 · validated civic_curation pubmed

Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors.

· J Med Genet · 2020 · PMID 32284345 · validated civic_curation pubmed

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

· Cancer Res · 2009 · PMID 19244107 · validated civic_curation pubmed

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

· Cancer Res · 2009 · PMID 19117982 · validated civic_curation pubmed

The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.

· Oncogene · 2000 · PMID 10828883 · validated civic_curation pubmed

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.

· J Clin Invest · 2024 · PMID 38687617 · validated civic_curation pubmed

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

· ACS Med Chem Lett · 2018 · PMID 29670690 · validated civic_curation pubmed

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

· Cancer Res · 2010 · PMID 20570890 · validated civic_curation pubmed

Systematic Functional Annotation of Somatic Mutations in Cancer.

· Cancer Cell · 2018 · PMID 29533785 · validated civic_curation pubmed

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

· Nat Genet · 2011 · PMID 22197931 · validated civic_curation pubmed

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

· Oncotarget · 2016 · PMID 26992226 · validated civic_curation pubmed

The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.

· EBioMedicine · 2015 · PMID 26097890 · validated civic_curation pubmed

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

· Proc Natl Acad Sci U S A · 2009 · PMID 19915144 · validated civic_curation pubmed

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

· Cancer Cell · 2008 · PMID 18394554 · validated civic_curation pubmed

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

· Mol Cancer Ther · 2009 · PMID 19671763 · validated civic_curation pubmed